284 related articles for article (PubMed ID: 20158913)
21. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
[TBL] [Abstract][Full Text] [Related]
22. VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI.
Hoang BH; Dyke JP; Koutcher JA; Huvos AG; Mizobuchi H; Mazza BA; Gorlick R; Healey JH
Clin Orthop Relat Res; 2004 Sep; (426):32-8. PubMed ID: 15346048
[TBL] [Abstract][Full Text] [Related]
23. Correlation of High-Grade Osteosarcoma Response to Chemotherapy with Enhanced Tissue Immunological Response: Analysis of CD95R, IFN-γ, Catalase, Hsp70, and VEGF.
Mustokoweni S; Mahyudin F; Setiawati R; Nugrahenny D; Hidayat M; Kalim H; Mintaroem K; Fitri LE; Hogendoorn PCW
Virchows Arch; 2024 Jun; 484(6):925-937. PubMed ID: 38748263
[TBL] [Abstract][Full Text] [Related]
24. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
25. Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study.
Rastogi S; Kumar R; Sankineani SR; Marimuthu K; Rijal L; Prakash S; Jalan D; Khan SA; Sharma MC
Int Orthop; 2012 Nov; 36(11):2315-21. PubMed ID: 23015149
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of COX-2 expression and correlation with Bcl-2 and VEGF expression, microvessel density, and clinical variables in classical Hodgkin lymphoma.
Koh YW; Park C; Yoon DH; Suh C; Huh J
Am J Surg Pathol; 2013 Aug; 37(8):1242-51. PubMed ID: 23851330
[TBL] [Abstract][Full Text] [Related]
27. Prognostic relevance of increased angiogenesis in osteosarcoma.
Kreuter M; Bieker R; Bielack SS; Auras T; Buerger H; Gosheger G; Jurgens H; Berdel WE; Mesters RM
Clin Cancer Res; 2004 Dec; 10(24):8531-7. PubMed ID: 15623635
[TBL] [Abstract][Full Text] [Related]
28. Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma.
Nathan SS; Huvos AG; Casas-Ganem JE; Yang R; Linkov I; Sowers R; DiResta GR; Gorlick R; Healey JH
J Orthop Res; 2008 Nov; 26(11):1520-5. PubMed ID: 18473395
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.
Mineo TC; Ambrogi V; Baldi A; Rabitti C; Bollero P; Vincenzi B; Tonini G
J Clin Pathol; 2004 Jun; 57(6):591-7. PubMed ID: 15166262
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.
Tabone MD; Brugières L; Piperno-Neumann S; Selva MA; Marec-Bérard P; Pacquement H; Lervat C; Corradini N; Gentet JC; Couderc R; Chevance A; Mahier-Ait Oukhatar C; Entz-Werle N; Blay JY; Le Deley MC
BMC Cancer; 2017 Jun; 17(1):419. PubMed ID: 28619014
[TBL] [Abstract][Full Text] [Related]
31. [Relationship between vascular endothelial growth factor expression and angiogenesis in osteosarcoma].
Zhao Y; Qiu GX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Dec; 23(6):619-22. PubMed ID: 12901110
[TBL] [Abstract][Full Text] [Related]
32. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
Choeyprasert W; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Anurathapan U; Hongeng S; Nartthanarung A
Asian Pac J Cancer Prev; 2014; 15(22):9823-9. PubMed ID: 25520112
[TBL] [Abstract][Full Text] [Related]
33. CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment.
Wang SW; Liu SC; Sun HL; Huang TY; Chan CH; Yang CY; Yeh HI; Huang YL; Chou WY; Lin YM; Tang CH
Carcinogenesis; 2015 Jan; 36(1):104-14. PubMed ID: 25330803
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma.
Kolev Y; Uetake H; Iida S; Ishikawa T; Kawano T; Sugihara K
Ann Surg Oncol; 2007 Oct; 14(10):2738-47. PubMed ID: 17687613
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemotherapy with high-dose methotrexate in osteosarcoma.
Mir O; Ropert S; Goldwasser F
Lancet Oncol; 2008 Dec; 9(12):1198. PubMed ID: 19038767
[No Abstract] [Full Text] [Related]
36. CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34.
Miyata Y; Sagara Y; Watanabe S; Asai A; Matsuo T; Ohba K; Hayashi T; Sakai H
Virchows Arch; 2013 Nov; 463(5):673-9. PubMed ID: 23975255
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.
Koh YW; Han JH; Yoon DH; Suh C; Huh J
Ann Hematol; 2017 Nov; 96(11):1883-1890. PubMed ID: 28842748
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy for osteosarcoma without high-dose methotrexate: a 12-year follow-up on 53 patients.
Tunn PU; Reichardt P
Onkologie; 2007 May; 30(5):228-32. PubMed ID: 17460416
[TBL] [Abstract][Full Text] [Related]
39. Expression and significance of pigment epithelium-derived factor and vascular endothelial growth factor in colorectal adenoma and cancer.
Yang Y; Wen W; Chen FL; Zhang YJ; Liu XC; Yang XY; Hu SS; Jiang Y; Yuan J
World J Gastrointest Oncol; 2024 Mar; 16(3):670-686. PubMed ID: 38577437
[TBL] [Abstract][Full Text] [Related]
40. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.
Tao X; Sood AK; Deavers MT; Schmeler KM; Nick AM; Coleman RL; Milojevic L; Gershenson DM; Brown J
Gynecol Oncol; 2009 Sep; 114(3):431-6. PubMed ID: 19524286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
